Actinium Pharmaceuticals $ATNM Remains Significantly Undervalued

The biotech sector has seen a sharp correction since late April. Since April 25th, the iShares NASDAQ Biotechnology Index (ETF) (IBB) has dropped more than 12%. If the sell-off continues over the next week, the biotech sector could very well end up in bear market territory.actinium logo

The sharp correction in the biotech sector though has also created some excellent buying opportunities. Indeed, some advanced clinical stage companies now look substantially undervalued. One such company is Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM). Read more